5-Amino-1MQ versus SLU-PP-332
5-Amino-1MQ and SLU-PP-332 are different small molecules, not peptides. They appear in metabolism-related discussions, but they act on different targets and cannot be treated as interchangeable materials or ranked from a shared headline.
5-Amino-1MQ is discussed in work on the enzyme NNMT. SLU-PP-332 is discussed in work on estrogen-related receptors, abbreviated ERRs. The sections below translate those names and separate what the cited experiments found from claims about personal weight loss or exercise.
How do the two molecular targets differ?
5-Amino-1MQ is a small-molecule NNMT inhibitor. SLU-PP-332 is a small-molecule ERR agonist. NNMT is an enzyme; ERRs are nuclear receptors. [[1]](https://pmc.ncbi.nlm.nih.gov/articles/PMC5826726/) [[2]](https://pubmed.ncbi.nlm.nih.gov/36988910/)
Inhibiting an enzyme and activating a transcriptional regulator change different parts of a biological system. A shared downstream measurement does not establish a shared mechanism. Start by specifying the target and the question, then decide which evidence would answer it.
A catalogue category is useful navigation. It does not establish that every compound grouped there has the same identity, molecular role or suitability for an experiment.
What did the 5-Amino-1MQ studies examine?
Neelakantan and colleagues characterized NNMT inhibitors, including 5-Amino-1MQ, using permeability, selected off-target and cellular measurements. Reported mouse outcomes included lower body weight and white adipose mass. [[1]](https://pmc.ncbi.nlm.nih.gov/articles/PMC5826726/)
Keep biochemical, cellular and animal observations in separate columns when reviewing that work. A selectivity panel covers the interactions it tested, rather than every possible interaction. Likewise, a downstream change should not be treated as a complete explanation of how that change occurred.
An evidence record is more useful when it preserves these distinctions than when it reduces the entire program to a broad promise about metabolism.
What did the SLU-PP-332 studies find?
Billon and colleagues examined SLU-PP-332 across ERR subtypes, measured muscle-cell respiration and mitochondrial-related responses, and reported increased exercise endurance in mice. These findings do not establish that the compound replaces exercise in people. [[2]](https://pubmed.ncbi.nlm.nih.gov/36988910/)
A later chemical-optimization study tested changes to the SLU-PP-332 scaffold through functional assays, gene-expression work and computational methods. Its analogues had different activity and property profiles. [[3]](https://pmc.ncbi.nlm.nih.gov/articles/PMC13112601/)
That is a reason to record exact chemical identity when comparing publications. An analogue, a parent compound and an unrelated molecule should not be merged because a summary uses a common research label. The experimental material must remain identifiable throughout the argument.
Does a metabolism headline establish a human benefit?
Record the compound, assay, comparator and endpoint before comparing results. Do not rank unlike studies by the largest numerical change when their models and methods differ.
| Tool | Target-level question | Evidence boundary |
|---|---|---|
| 5-Amino-1MQ [[1]](https://pmc.ncbi.nlm.nih.gov/articles/PMC5826726/) | NNMT inhibition and downstream measurements | Cell and mouse findings do not establish human outcomes |
| SLU-PP-332 [[2]](https://pubmed.ncbi.nlm.nih.gov/36988910/) | ERR activation and metabolic gene programs | Mouse endurance is not a human exercise-replacement result |
| SLU scaffold analogues [[3]](https://pmc.ncbi.nlm.nih.gov/articles/PMC13112601/) | How structure changes activity and properties | Related structures are not interchangeable |
The supplier comparison guide provides a framework for checking material identity and documentation. Its principles also apply to small-molecule research materials. A label, catalogue category or purity percentage cannot substitute for the target-specific evidence required by an experiment.
Are these compounds peptides?
No. These are small-molecule research tools. Their appearance alongside peptides in a catalogue does not change their chemical class.
Can one be substituted for the other?
Not on the basis of a shared metabolic-research label. Their targets and experimental questions differ; suitability must follow the specified research requirement.
Research material information: 5-Amino-1MQ (50mg), SLU-PP-332 (5mg). These products are coming soon; use the notification bell on the product page for an availability email.
Does the phrase exercise mimetic mean it replaces exercise?
No. That phrase describes selected experimental responses, not proof that a product reproduces all the effects of exercise in people. Check the model, measured outcome and tested compound before repeating the claim.
Does a Coming soon page establish availability or a launch price?
No. It identifies a forthcoming catalogue item and lets a reader request an availability notification. Product status, pricing and applicable testing need their own confirmed information.
Primary references
- Neelakantan et al.: NNMT inhibitors in cells and obese mice
- Billon et al.: ERR agonism and exercise-related mouse measurements
- Okda et al.: Chemical optimization of the SLU-PP-332 scaffold
EPS documentation
Use the research catalogue to check the exact name, labelled amount and format. The COA library publishes the original Janoshik reports selected for EPS, retaining the original report client name and any missing batch fields. Literature findings and another supplier's analytical results are not evidence about an EPS batch.